 OXFORD, United Kingdom, May 04, 2021 GLOBE NEWSWIRE -- Vaccitech plc NASDAQ: VACC, a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced the closing of its initial public offering in the United States of 6,500,000 American Depositary Shares ADSs representing 6,500,000 ordinary shares at an initial public offering price of 17.00 per ADS. The gross proceeds from the offering were approximately 110.5 million. Vaccitechs ordinary shares began trading on the Nasdaq Global Market in the U.S. under the ticker symbol VACC on April 30, 2021. All ADSs sold in the offering were offered by Vaccitech. 